Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Janux Therapeutics (JANX) Total Liabilities (2020 - 2025)

Historic Total Liabilities for Janux Therapeutics (JANX) over the last 6 years, with Q3 2025 value amounting to $48.2 million.

  • Janux Therapeutics' Total Liabilities rose 2388.8% to $48.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $48.2 million, marking a year-over-year increase of 2388.8%. This contributed to the annual value of $38.7 million for FY2024, which is 742.41% up from last year.
  • As of Q3 2025, Janux Therapeutics' Total Liabilities stood at $48.2 million, which was up 2388.8% from $41.7 million recorded in Q2 2025.
  • Over the past 5 years, Janux Therapeutics' Total Liabilities peaked at $48.2 million during Q3 2025, and registered a low of $12.0 million during Q2 2021.
  • Over the past 5 years, Janux Therapeutics' median Total Liabilities value was $38.5 million (recorded in 2024), while the average stood at $34.0 million.
  • Per our database at Business Quant, Janux Therapeutics' Total Liabilities soared by 24545.23% in 2022 and then tumbled by 2031.8% in 2024.
  • Quarter analysis of 5 years shows Janux Therapeutics' Total Liabilities stood at $13.5 million in 2021, then surged by 220.59% to $43.3 million in 2022, then dropped by 16.67% to $36.1 million in 2023, then rose by 7.42% to $38.7 million in 2024, then increased by 24.46% to $48.2 million in 2025.
  • Its last three reported values are $48.2 million in Q3 2025, $41.7 million for Q2 2025, and $38.3 million during Q1 2025.